We have found that, in general, the preferred targets to develop antidepressants continue to be those aiming the serotoninergic system and, in a less extend, the noradrenergic one; but, more particularly, those that aim multiple targets are preferred due to problems concerning the efficacy of highly selective drugs.
INTRODUCTION
According to the World Health Organization, depression is a common condition that affects about 121 million people worldwide. 1 Moreover, neuropsychiatric disorders are the second largest cause of disease burden in the world after cardiovascular diseases, and the number of people affected with these disorders is likely to increase further as the population ages. The economic costs to society are enormous, with one estimate from the International Labour Organization placing them at 3-4% of the gross national product (GNP) in EU member states. 2 The high cost of care and loss of workplace productivity are due to lack of treatment or limitations of currently used drugs.
The pathophysiological origin of this disease continues to be unknown and it was not until the mid 1960s that a biochemical explanation for the phenomenon became accepted. The monoamine theory, the most widely accepted, 3 states that depression is a result of a deficiency of brain monoamine (noradrenaline -NA-and/or serotonin -5-HT-) activity and that an approach to treat depression is to enhance this monoaminergic activity. In a normal brain, neurotransmitters such as NA or 5-HT are liberated in the synapse by the presynaptic neuron. While in the synapse, the neurotransmitter can interact with the postsynaptic neuron to exert its normal effect, it can be metabolized or it can be reuptaken by the presynaptic neuron. As well, in the synapse, the neurotransmitter can interact with some receptors in the presynaptic neuron, known as autoreceptors, which inhibit its activity. Therefore, possible approaches towards increasing the monamine level in the brain would be:
(a) to block the presynaptic inhibitory autoreceptors, mostly the α 2 -adrenoceptors (α 2 -AR), and some of the 5-HT subtype receptors (1A or 1B), (b) to block the monoamine reuptake mechanisms from the synapse, by means of 5-HT or NA reuptake inhibitors: SSRIs, SNRIs, or NRIs, (c) to inhibit the metabolic pathways (monoamine oxidase inhibitors, MAOIs), (d) to act directly on monoaminergic neuron activity.
What is usually considered to be the first generation of antidepressants was developed after the Second World War, and some of the most important compounds developed during this period were found by serendipity. The first two types of drugs used for the treatment of major depression were the MAOIs and the tricyclic antidepressants.
Iproniazid, which can be considered the first modern antidepressant, is a MAOI and was originally developed as an antituberculosis drug in the 1950s. After promising preliminary results, this compound was prescribed to patients with major depression from 1957.
Although it is no longer used because of toxic side effects, it led to further research in the idea of using drugs to alleviate depression. The first tricyclic antidepressant developed was Imipramine, which was conceived originally for the treatment of schizophrenia. Later on different studies showed that this drug increased the monoamine activity, mostly NA and 5-HT, by inhibiting their reuptake. 4 These findings led to the development of the second generation of antidepressive agents, which targeted neurotransmitters reuptake systems and transporters. This very popular class of antidepressants, known as the selective serotonin reuptake inhibitors or SSRIs, was developed trying to find antidepressant agents without the unwanted side effects of the MAOIs or the tricyclics. A typical drug of this generation is Fluoxetine (Prozac) which was discovered and put in the market by 1987. Drugs of this second generation are better tolerated by the body than those of the first one, but they still present a variety of uncomfortable secondary effects, including slow onset of action, sexual dysfunction, insomnia and weight gain. Thus, there remains a need for more efficient, well-tolerated and more rapidly acting antidepressants. second generation, the SSRI fluoxetine; and third generation, the α2-AR antagonist mirtazapine.
The current approach, which represents the third generation, follows the monoamine theory, and consists in new compounds targeting the autoreceptors, specifically the 5-HT receptors such as 5-HT 1A or 5-HT 1B , and the NA receptor, α 2 -AR. 6 For example, the negative feedback loop associated with the presynaptic 5-HT 1A receptors is considered to be responsible of the interval observed, in many patients, between the administration of SSRIs and the observed therapeutic action. In recent years, the focus seems to have changed to develop compounds with dual action, for example affinity for the 5-HT autoreceptors and inhibitory activity at the 5-HT transporter (SERT), and they seem to be the next generation of antidepressants. 7 Regarding NA autoreceptors, Mirtazapine (Remeron), an α 2 -AR antagonist with blocking action on 5-HT 2A , 5-HT 2B and 5-HT 3 , was found and introduced in the market in 1994. Further, the search for dual agents targeting not only the α 2 -AR but also the NA transporter (NAT) or the SERT is being pursued.
To date, these have been the most typical targets for the development of antidepressant agents and, several reviews have been devoted to these therapies and possible new approaches to the treatment of depression. 8, 9, 10, 11 Most of the drug discovery efforts have focused on targeting 5-HT or NA systems, trying to improve selectivity, onset or safety, but based mostly on the same mechanisms of action of the older MAO inhibitors and tricyclic antidepressants. Even agomelatine, which is a drug recently authorized targeting the melatonin system, is also a 5-HT 2C antagonist. 12 Hence, despite large amounts of money devoted to this research no new medications have appeared in the market. There is no doubt that today's antidepressants are in general safe and effective; however, still there are serious side effects, and less that 50% of patients show full remission.
Therefore, more effective and safer antidepressants with faster onset are still needed. 8 Although all available antidepressants are attributed to the enhancement of the extracellular availability of 5-HT and/or NA in the brain, the cellular and biochemical mechanisms underlying the therapeutic actions of these drugs remain unclear. Another neurotransmitter that plays a role in mood is dopamine (DA). Dopaminergic agents have been used to manage depression when conventional antidepressant treatments fail, and thus, DA could be involved in the pathophysiology of depression for a subset of patients. 13 Moreover, chronic treatment with antidepressants produces a number of changes in dopaminergic neurotransmission, in particular a sensitization of behavioural responses to agonists acting at DA D 2 /D 3 receptors within the nucleus accumbens.
14 Additionally, a new and complementary theory is arising, the neurotrophic hypothesis, based on the findings of underdeveloped hippocampus in depressed patients, due to the critical role of neurotrophic factors that control brain development and plasticity.
Moreover, it seems that first generation antidepressants and SSRIs act also by increasing these neurotrophic factors and reducing those hippocampus alterations described. 15 In our search on the worldwide Patent database managed by the European Patent Office (EPO) using the esp@cenet searching engine, 16 we have found that during the years 2005 to 2008 only very few new targets have been addressed. In the following sections, we will present the results of this search organized in terms of which receptors and/or transporters the patented compounds target. First, those patents related to drugs aiming to monoamine transporters (5-HT and NA) independently or as dual agents will be examined. Secondly, those antidepressants that have been patented as targeting the monoamine receptors (singly or in a dual manner) will be discussed. After that a miscellaneous section dealing with those patented drugs that aim to different targets than monoamine systems will be presented.
TARGETING MONOAMINE TRANSPORTERS

Targeting the Serotonin Transporter
Serotonin (5-hydroxytryptamine, 5-HT) is a monoamine neurotransmitter that plays an important role in different behaviours including sleep, appetite, memory, and mood. In the synapse, 5-HT can interact with both pre-and postsynaptic receptors. Yet, just after reacting with the receptors, it is important that 5-HT is removed from the synapse. This process, known as reuptake, determines the receptor activation and is performed by the Serotonin Transporter (SERT).
Selective serotonin reuptake inhibitors (SSRIs) act at the SERT and block the reuptake 
Targeting Serotonin and Noradrenaline Transporters
In the same way that a reuptake system is required to keep equilibrium in the levels of 5-HT in the synapse, other neurotransmitters such as NA have their own transporters.
Again, considering that depression seems to be a consequence of depletion on monoamines (NA and 5-HT) in the brain, it seems just logical to inhibit both reuptake In addition, a patent from 2007 reports some 2-(1H-indolylsulfanyl)benzylamine derivative as a compound which has a combined effect of 5-HT reuptake inhibition and NA reuptake inhibition and is useful as an antidepressant. 21 
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Finally, a patent on 3-aryloxy-3-substitute propanamines ( Figure 2c ) and their use in inhibiting 5-HT and NA reuptake has been issued last year by Natco Pharma Ltd.
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Additionally to the transporter inhibition test, several animal experiments were performed to asses the antidepressant activity of these compounds. Thus, Maximum
Tolerance Dose, Gross Behavioural, Force locomotor activity, and Immobility test studies in mice were performed.
In summary, newer dual-acting SNRIs antidepressants appear to possess a more favorable safety and tolerability profile. These drugs also may have an efficacy advantage over SSRIs in treating the painful physical symptoms of depression and in achieving remission of all symptoms of depression.
Targeting Serotonin transporter and receptors
SSRIs have been a big success in treating depression and related illnesses and they have become some of the most prescribed drugs. However, they have a slow onset of action, (taking several weeks to produce full therapeutic effect) and they are effective in less than two-thirds of patients. Moreover, it has been suggested that even though the levels of 5-HT increase by the blockade of SERT, the excess of 5-HT activates the autoreceptors (5-HT 1A ), causing a decrease in 5-HT release in major forebrain areas. 23 For that reason, a dual agent that blocks SERT and interact with the inhibitory 5-HT autoreceptors will increase even further the levels of the neurotransmitter in the synapse.
Such a multitarget therapy has been strongly pursued by Wyeth Corporation; hence, in the last four years they have produced a large number of patents claiming improved compounds which both inhibit SERT and are antagonists of the 5-HT1A autoreceptor. In all cases, to determine the affinity of the compounds for the SERT, they followed a protocol similar to that used by Cheetham et. al. 51 by measuring the compound's ability to displace 3 H-paroxetine from male rat frontal cortical membranes The high affinity for the 5-HT 1A receptor was established by testing the claimed compound's ability to displace 
Targeting the Serotonin transporter and other non-Adrenergic receptors
Dopamine D 2 receptor
Recently, clinical psychiatrists are using antidepressants for the treatment of schizophrenia. Schizophrenia is a mental disorder characterized by impairments in the perception or expression of reality and by significant social or occupational dysfunction.
This condition shows two types of symptoms: cognitive, emotional, and behavioural excesses ('positive' symptoms) and deficits ('negative' symptoms) which are somehow related to depression. Positive symptoms of schizophrenia are thought to be consistent with an excessive DA transmission, whereas negative symptoms are more likely to be related to prefrontal abnormalities (lower metabolic activity, i.e. hypofrontality). 69 In 1997, the combination of a SSRI, such as fluoxetine, with a dopaminergic antipsychotic agent, such as olanzapine, was described as an improved treatment for psychosis. with a dopaminergic antipsychotic agent, such as olanzapine, results in an improved treatment for psychosis. 70 Thus, this company considered that compounds with dopaminergic and serotonergic profiles will be useful in the treatment of psychosis and depression, and maybe other mental illnesses caused by disorders of the dopaminergic and serotonergic systems such as anxiety or obsessive compulsive disorder. 
Opioid receptors
The monoamine reuptake inhibitors used for therapy of depression and anxiety are also used for treatment of chronic pain. It seems that, in addition to the antidepressant actions, SNRIs lead to an independent analgesic action. Monoamine reuptake inhibitors are employed clinically for monotherapy of neuropathic pain, and also as an adjuvant to opiates for treatment of chronic pain. 86 Considering that chronic pain is accompanied by anxiety or depression in many patients, a compound that can acts as μ-opiate agonist and an inhibitor of SERT and/or NA transporter would be very attractive. Exactly that is what was achieved by Gruenenthal GmbH with a family of C-(2-phenyl-cyclohexyl)-methylamine compounds. 
Cannabinoid receptors
There are two subtypes of Cannabinoid receptors, CB 1 , the main target for cannabinoids in the brain, and CB 2 , and detailed information on these receptors, CB 1 receptor modulators, and their pharmacological activities are the subject of recent reviews. 94, 95, 96 Treatment of the CB 1 receptor has strong effects on anxiety and stress-related behaviours suggesting that CB 1 ligands might be antidepressant. However, to date, agents that both promote and attenuate CB 1 receptor activity have been reported to be beneficial. 97 Based on the idea of the observed commonality of different mental diseases, the company Solvay patented a series of compounds combining cannabinoid CB 1 antagonism with SERT inhibition that could be useful to treat conditions where independently targeting these systems is potentially effective, such as psychosis, anxiety, or depression. They claimed that attacking such disorders simultaneously via two different mechanisms of action can have synergistic effects. 
TARGETING MONOAMINE RECEPTORS
Targeting Serotonin receptors
The 5-HT superfamily of receptors comprises seven different classes (5-HT 1 -5-HT 7 ) that are split into a total of 14 different subclasses. 99 In a World Patent Application published in 1995, 100 it was claimed that an antagonist of the 1D subtype of the 5-HT receptor in combination with a 5-HT 1A antagonist can be used to treat CNS disorders such as depression and generalized anxiety between other CNS conditions. Moreover, Maura et al. 101 have stated that administration of agonists selective for 5-HT 1A receptors or for 105, 106 This receptor subtype was discovered in 1993 and since then has become a very valuable target. 107 They are unique in that they show a very low sequence homology with the other 5-HT receptor subtypes (lower than 40%). Functionally, it is considered to be involved in the regulation of the circadian rhythms and it is known that the interruption of these rhythms is related to CNS disorders such as depression.
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In 2007, Esteve produced a different family of compounds, indene derivatives ( Figure   6b ), which are claimed to be 5-HT 6 receptor modulators with application in depression between other conditions. 109 Compounds with affinity towards 5-HT 6 receptors are suitable for anxiety and depression as shown by several authors. 110, 111, 112, 113, 114 Moreover, it has been proved that typical and atypical antipsychotics show a high affinity to the 5-HT 6 receptors. 115, 116, 117, 118 This would be very relevant in developing dual therapies for the treatment of depression and schizophrenia. 
Targeting  2 -Adrenoceptors
Vast research has been performed in the area of serotonin receptors, but investigations centred in the noradrenergic system remain less explored. In particular, it is well known that central noradrenergic transmission is regulated by inhibitory α 2 -ARs autoreceptors which are expressed on both somatodendritic areas and axon terminals. Hence, considering that the activation of these α 2 -ARs induces an inhibition of NA release in the brain, it that has been proposed that depression is associated with a selective increase in the high-affinity conformation of these α 2 -ARs in the human brain. 125, 126 This enhanced α 2 -AR activity could be implicated in the deficit in noradrenergic transmission described in the aetiology of depression.
Thus, chronic treatment with antidepressants induces an in-vivo desensitization of the α 2 -ARs regulating the local release of NA. 127 Thus, the development of selective α 2 -adrenoceptor antagonists can be considered as a new and effective therapeutical approach to the treatment of depressive disorders. It has been demonstrated that the administration of different α 2 -AR antagonists both locally in the locus coeruleus or systemically increases the release of NA in the prefrontal cortex. 128, 129 Moreover, α 2 -AR antagonists are also able to enhance the increase of NA induced by selective reuptake inhibitor antidepressant drugs. 130 Prescriptions of the known α 2 -AR antagonist Mirtazapine (Remeron) have increased steadily during the last years. However, this drug still shows unwanted effects such as somnolence, weight gain or dizziness and a long onset of action. Furthermore, in a very recent study it has been shown that only 80% of depressive patients respond to the current antidepressants and that only a 58% achieve remission from their condition. 131 Hence, there is still a need for new antidepressants with fewer secondary effects, faster onset and a better understanding of their action. (Figure 7) , in which both a pyridine ring and a benzene ring are present and to which is bonded an N-alkyl piperidene group intended for psychotherapeutic and psychiatric treatments. Even though the pharmacological target seems not to be declared, the author mentions that related antidepressants to the object of the patent are Tolvon and Remeron, which are drugs based on respectively mianserin and mirtazapine both known α 2 -AR antagonists. 134 Unexpectedly, a family of compounds targeting the α 1 -AR subtype (and not the α 2 -AR) has been patented for the treatment of CNS conditions. These N-substituted 1-benzyl- 
TARGETING OTHER SYSTEMS/RECEPTORS
Targeting other CNS receptors
Glycine is the simplest amino acid and is an important inhibitory neurotransmitter in the brain. Glycine not only has its own receptor (an ion gated channel that conducts chloride anions into the postsynaptic cell), but also binds in a specific site of the NMDA receptor activating the receptor and facilitating the binding of glutamate. Several strategies have been employed as therapeutic approaches to empower NMDA receptor function via activation of the glycine activating site. These include direct interaction with the ligand binding site using agonists such as glycine, and blockade of the glycine reuptake site, GlyT1, in order to increase synaptic glycine levels. 141 In general, glycine receptor agonists/reuptake inhibitors are mainly developed for schizophrenia. 153 Similarly, Hermann proposed the use of ketamine for treating depression since it is a NMDA antagonist and has also been found to bind to opioid receptors (μ type) and sigma receptors. produced different arylpiperazine derivatives with a good inhibition of the D 3 receptor and therefore application as antidepressants. 157, 158 It has been demonstrated that the inhibition of nicotinic acetylcholine receptors in the brain contributes to the antidepressant effects of amitriptyline. 159 Based on this finding
Binder prepared enantiomerically pure hexahydropyrrolo cyclopentapyridine derivatives, as central nicotine receptor subtype agonists for treating depression. 160 A new emerging neuroreceptor for analgesics is the vanilloid receptor 1, and this receptor has found application for the treatment of depression as well. Hence, Gruenenthal GmbH has patented new spiro isoxazole cycloalkane derivatives that target the vanilloid receptor 1 and can find application as antidepressants. 161 Increasing amounts of data suggest that affective disorders might be related to deregulation of the hypothalamic-pituitary-adrenal axis, and Vasopressin seems to be involved in the regulation of this axis. In Abbott, they have targeted the Vasopressin receptors to develop CNS agents with application in depression, between other conditions, and with this objective have produced a number of substituted oxindole derivatives. 162, 163 Finally, two new targets have been considered useful for the treatment of neuropsychiatric conditions. On the one hand, sigma receptors have been found to be involved in psychosis and other neurological conditions. Most of the studies imply that sigma receptors are membrane receptors involved in signalling transduction. In Esteve Laboratories a family of fused pyrazole derivatives has been prepared as inhibitors of sigma receptors with application in depression. 164 On the other hand, a sodium/hydrogen exchanger protein has been chosen by Sanofi Aventis as target for substituted 2-aminoimidazoles with activity as tranquilizer and antidepressant between other applications. Additionally, Servier has developed three different families of compounds. First they produced some 3-acylaminoethyl-3-phenylthio-benzothiophene derivatives (Figure 8) that act on the MT 1 , MT 2 or MT 3 melatonin receptors and on the 5-HT 2C receptor subtype as well. 169 In 2008, they patented new indole derivatives targeting MT 1 and MT 2 melatonin receptors which seem to be useful to treat sleep disturbance, stress, anxiety and depression between many other disorders. 170 Finally, they have found new naphthalene derivatives (Figure 8 ) related to the structure of melatonin that bind to melatonin receptors MT 1 and MT 2 and show antidepressant activity. 171 Agomelatine is a chemical, structurally related to melatonin that acts as an agonist at the melatonin receptors and as an antagonist at 5-HT 2C receptors. This compound has been tested in the Force Swimming Test for depression showing antidepressant activity and can be considered as a good drug for this condition. 12 Thus, continuing with their search for new antidepressants, Servier patented the use of agomelatine as antidepressant, neuroleptic and sedative among other CNS applications, 172 and also as a drug to treat generalised anxiety disorder. 173 Later on, in 2008, they have also patented the use of agomelatine to treat major and seasonal depression. 174 Melanocortins are a group of endogenous peptide hormones. Through binding to five melanocortin receptors (MC 1 -MC 5 ), these peptides exert multiple influences on the host, including anti-inflammatory and immunomodulatory effects. The MC 4 receptor, which is predominantly expressed in the CNS, has become the focus of much attention in recent years because of the critical roles it plays in a wide range of functions, including feeding, sexual behaviour, and stress. Recent development of selective antagonists of this receptor has provided pharmacological evidence that its blockade could be a useful way of alleviating anxiety/depression, pain, and addiction to drugs of abuse. 175 One patent has been found dealing with 1,2,6-trisubstituted benzimidazole derivatives and imidazopyridine analogues, which are melanocortin MC 4 receptor ligands and can be used for the treatment of depression. 176 Additionally, the work of Chaki et al. on SSRI/MC 4 antagonists should be mentioned.
They have developed MCL0042 which is a non-peptidic antagonist of the MC 4 receptor and also an inhibitor of the SERT. 
Targeting enzymatic systems
Other different targets have been aimed for the development of new antidepressants. For example, Takeda Pharmaceutical has issued two patents describing a series of benzofuranes, which are inhibitors of the protein kinase B (PKB), for the treatment of neuropsychiatric disorders. 178, 179 PKBs are involved in the production of inositol triphosphate (IP 3 ) and it has been suggested that a signal transduction from IP 3 is involved in nerve cell survival, nerve regeneration or nerve differentiation. However, a relationship between PKB activation and prevention or treatment of depression, anxiety, or manic-depressive psychosis has not been confirmed, and therefore, the actual application of these benzofuranes as antidepressants is doubtful. In general, a turn towards multiple target drugs is observed in these new patents, probably due to problems concerning efficacy of highly selective drugs emerging from rational drug discovery and genomic programmes. Thus, we believe that more innovative targets should be explored for the treatment of depression and that new efforts should be devoted to develop drugs that, by targeting CNS neurotransmitter systems in a multi-targeted way, can be used as therapies for both depression and schizophrenia. This will benefit the field in terms of a better understanding of both neuropsychiatric conditions and the interlinked mechanisms involved. It will also be a very profitable and well accepted market approach.
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